Best Grants for Cancer Nonprofits in Missouri

The McKesson Foundation Grant provides funding above $25,000 to support health equity initiatives across North America. Founded in 1943, its mission focuses on removing barriers to quality healthcare for vulnerable communities. The foundation prioritizes projects that align with strategic pillars: reducing cancer burdens, preparing the healthcare workforce, and enhancing crisis response. Eligible organizations include national and local nonprofits. Funding is limited to specific regions and assessed based on demonstrated need and expected impact.

The Elsa U. Pardee Foundation has been a pioneer in cancer research funding since 1944, providing over $110 million to more than 300 institutions across the U.S. It supports innovative approaches by both new and established researchers, ensuring diverse ideas receive necessary funding. Additionally, the Foundation addresses immediate financial needs for cancer patients, allocating about one-third of its grants to assist those in need. This dual focus on research and patient support distinguishes the Foundation in the fight against cancer.

The Barney Family Foundation Grant focuses on improving early education and advancing medical research, particularly in cancer and Alzheimer’s. It supports organizations that demonstrate a clear plan to enhance children's life experiences and educational opportunities for those in grades K-8. Grants typically range from $5,000 to $50,000, prioritizing established entities while welcoming startups. Eligible applicants must have 501(c)(3) status, and the Foundation does not fund individual requests or political activities.

The Brees Dream Foundation Grant aims to enhance the lives of cancer patients while providing essential care, education, and opportunities for children and families in need. With the support of generous donors and partners, the Foundation is dedicated to advancing cancer research and offering vital resources to those facing challenges. This commitment reflects a profound dedication to improving quality of life and fostering hope in communities.

The Pershing Square Sohn Cancer Prize is awarded to early-career scientists in the New York area who are pursuing innovative cancer research. Established by the Pershing Square Foundation in partnership with The Sohn Conference Foundation, the prize offers $250,000 annually for up to three years. With a commitment of over $49 million since 2013, the Alliance aims to accelerate cancer cures by fostering collaborations between academia and industry, providing a unique network and access to vital resources for groundbreaking research.

Sanofi Philanthropic Donations support non-profit organizations aligned with Health Equity, STEM Education Equity, and Local Communities. Applications are accepted year-round, with a review process of 8 to 16 weeks. The initiative focuses on improving healthcare access, fostering innovation, and addressing social determinants of health. Sanofi emphasizes collaboration and sustainable solutions, advocating for equal opportunities in health and education, and nurturing future talent to tackle medical challenges.

The Prevent Cancer Foundation is launching a $100,000 community grant program for 2024-2026, focusing on patient navigation for cancer prevention and early detection. Community-based organizations can apply for funding over two years to enhance their efforts. Priority will be given to applicants demonstrating best practices, established community partnerships, and initiatives that address health disparities. Note that the application cycle opens in 2026, emphasizing the importance of proactive health measures.

Exelixis Grants & Giving focuses on impactful charitable contributions, supporting non-profit organizations in community support, healthcare-related initiatives, independent patient assistance, medical education, and sponsorships. Their aim is to enhance oncology care, particularly for renal cell carcinoma and other cancer types, while ensuring proposals are submitted within specified timelines. Exelixis partners with organizations dedicated to improving patient outcomes and community health, demonstrating their commitment to making a difference beyond medicine.

The ASTRO Medical Student Fellowship Award for Underrepresented Populations aims to enhance diversity in radiation oncology by supporting medical students from underrepresented backgrounds. Awardees receive a $6,000 package, including a stipend for an eight-week training program, funds for travel expenses, and mentorship opportunities. This initiative is part of ASTRO's broader mission to advance patient care and professional development in the field of radiation oncology, fostering an inclusive environment in medical education.

The Myelodysplastic Syndromes (MDS) Research Fund Grant, established by the Vera and Joseph Dresner Foundation, aims to enhance research and treatment of MDS and related blood disorders. This fund supports innovative projects addressing etiology, biology, genetics, prognosis, treatment, symptom management, and quality of life. It offers up to $125,000 for Early Career Awards and $250,000 for Established Investigator Awards, facilitating significant advancements in the field.

The Mark Foundation Emerging Leader Award supports innovative cancer research led by early career investigators. Aimed at high-impact, high-risk projects, this grant is available to those employed by U.S. or Canadian non-profit academic institutions. Eligible applicants must be within three to eight years of starting their independent faculty research appointment. This award emphasizes multi-year independent funding and is not intended as the main funding source for the laboratory, ensuring that diverse research efforts are encouraged.

The Gilead Research Scholars Program in Oncology supports innovative research from emerging investigators worldwide, focusing on scientific understanding and progress in cancer treatment. Launched in 2008, it offers financial support of up to $180,000 over two years to junior faculty who meet eligibility criteria. The program emphasizes diversity and aims to reduce barriers for underrepresented groups in research, fostering a more inclusive landscape in addressing unmet medical needs.

The Deluxe Corporation Foundation's ERG Grant Program supports diverse and inclusive initiatives by empowering employee resource groups (ERGs) to partner with nonprofits addressing relevant social issues. Each of the ten ERGs will award a $25,000 grant to a selected organization, fostering community impact and collaboration. The foundation, established in 1954, has invested over $109 million in charitable causes, focusing on financial literacy, education, and community support to enhance lives and promote entrepreneurship.

The NIH is inviting applications for interventions aimed at enhancing cancer screening and preventive services in underserved populations. This initiative focuses on addressing barriers to healthcare access and promoting timely follow-up on abnormal findings. Collaborations with community partners are encouraged to foster effective outreach. The program particularly seeks to engage patients, clinicians, and healthcare settings in improving health equity and outcomes in cancer prevention.

The National Cancer Institute (NCI) seeks to enhance the validation of biomarkers and assays for cancer detection and treatment through its UH3 funding mechanism. This initiative supports multi-disciplinary collaborations to validate existing assays over three years using clinical trial specimens. Emphasis is placed on harmonizing laboratory tests and validating pharmacodynamic markers. Projects should not focus on early-stage technology development but aim for integration into clinical studies as investigational assays.

The National Cancer Institute (NCI) invites applications for the validation of molecular, cellular, and imaging markers for cancer detection and treatment. This funding opportunity supports both analytical and clinical validation phases, emphasizing multi-disciplinary collaboration. The UH2 phase focuses on analytical validation, while the UH3 phase extends to clinical validation using well-annotated biospecimens. Proposals should justify the relevance of assays for clinical use and may include harmonization efforts across laboratories.

The Emerging Global Leader Award (K43) offers essential research support and protected time for early career scientists in low- and middle-income countries. This program, aligned with NIH's clinical trials policy, aims to cultivate independent research careers by providing mentorship and funding over three to five years. Eligible candidates must hold a junior faculty position at an accredited LMIC institution, fostering the growth of research capacity in their regions.

The Fogarty Emerging Global Leader Award supports early career research scientists from low- or middle-income countries (LMIC) by providing research funding and mentored career development for three to five years. This program encourages LMIC scientists in health-related fields to develop projects aligned with their country's health priorities, fostering independent research careers within their institutions. Applications are welcomed from junior faculty members, enhancing global health research and capacity in LMICs.

The Extramural Discovery Science Accelerator Award supports the commercialization of ongoing cancer research projects, focusing on experiments that facilitate technology validation and de-risking. Applications are accepted on a rolling basis, with a budget of up to $75,000 for one year. This award encourages independent investigators at any career stage to advance their technologies, with a strong emphasis on commercial viability and collaboration within a learning community.

The Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) aims to enhance cancer treatment by integrating imaging and liquid biopsy assays. This initiative, led by the National Cancer Institute (NCI), encourages grant applications focused on assessing therapy responses and resistance emergence in patients. Key deadlines for submissions span from February 2025 to January 2028, providing ample opportunities for researchers to contribute to this vital area of cancer research.

This funding opportunity invites applications for R01 grants focused on molecular imaging methods to explore cancer inflammation in vivo. It aims to enhance understanding of dynamic interactions between inflammation and cancer through innovative imaging techniques. The initiative encourages collaborations between cancer researchers and imaging scientists to leverage molecular imaging for identifying cellular physiology changes in response to treatment. Deadline dates for applications range from February 2025 to October 2027, emphasizing timely submission for prospective researchers.

The Tobacco, Alcohol, and Cannabis Policy Research for Health Equity (R21 Clinical Trial Optional) aims to fund projects that explore policies related to tobacco, alcohol, and cannabis in the U.S. The focus is on understanding how these policies affect usage and exposure among disadvantaged populations. Engaging community organizations is essential for promoting equity in cancer prevention. This initiative is crucial for advancing health equity and reducing disparities in substance use.

The Tobacco, Alcohol, and Cannabis Policy Research for Health Equity grant aims to support research on policies affecting tobacco, alcohol, and cannabis use in the U.S. This initiative focuses on how these policies impact populations facing health disparities. Key components include engaging community organizations to advance equity in cancer prevention. Important deadlines for applications range from February 2025 to October 2027, providing opportunities for both standard and renewal submissions.

This grant aims to enhance applied regulatory science research for the evaluation and treatment of cardiotoxicity associated with oncology therapeutics. The initiative will facilitate collaboration with the FDA to develop effective methodologies and solutions, ensuring that research outcomes are directly relevant to regulatory decision-making. Key activities include regular communication with funded investigators and a focus on improving detection and management of cardiotoxicity, ultimately leading to impactful publications and presentations.

The 2026 Vilcek Prizes for Creative Promise in Biomedical Science will award three $50,000 prizes to exceptional young immigrant scientists in the U.S. This prestigious prize recognizes innovative research contributions in biomedical science. Eligible candidates must be under 38 years old, hold a doctoral degree, and have made significant achievements in their field. The Vilcek Foundation aims to highlight the impact of immigrant scientists on the advancement of biomedical research, fostering diversity and excellence.

The Academic Research Enhancement Award (AREA) supports small-scale research grants for institutions with limited NIH funding, emphasizing biomedical research experiences for undergraduates. Eligible institutions must award baccalaureate science degrees and have received no more than $6 million in NIH support over the past seven years. This initiative aims to enhance the research environment at these institutions, fostering student involvement in research activities.

The NCI Continuing Umbrella of Research Experiences (CURE) Non-Mentored Research Scientist Career Development Award (K22) aims to support postdoctoral fellows from underrepresented backgrounds in transitioning to tenure-track positions. This award provides essential funding for salary and research support for three years, enabling candidates to establish independent biomedical careers. Key deadlines for applications range from February 2025 to October 2027, ensuring ample opportunity for eligible researchers to secure funding for their career development.